Why Moderna (MRNA) Stock Rose 6.97% in 10 Minutes on Nov 6, 2026
MoveSurge measured ten earlier Moderna headlines with an attributed reaction between Aug 8, 2026 and Nov 5, 2026. The largest was +64.73% in 15 minutes, on Aug 19, 2026.
- MRNA rose 6.97% in the 10 minutes after the 06:45:00 ET headline, from $237.00 to $253.51.
- 33,924 shares changed hands in those 10 minutes, 30.8 times the stock's normal volume for that stretch of the session.
- The headline crossed in pre-market trading, 2 hours 45 minutes before the 9:30 ET open.
06:45:00 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| MRNA Volume 30.8× normal in 15 min |
237.00 | 237.00 | 245.02 | 253.51 | +3.38% | +6.97% |
Moderna (MRNA) shares rose 6.97% in the 10 minutes after this headline reached the MoveSurge news feed at 06:45:00 ET on Friday, November 6, 2026: “Moderna says it is conducting a limited U.S. launch of its seasonal influenza vaccine for the 2026–2027 season, with approval coming after the annual contracting cycle”
MRNA in the first 10 minutes
From a reference price of $237.00 just before the headline, the stock was up 3.38% after one minute and up 6.97%, at $253.51, after 10 minutes. The move kept building after the first minute. 33,924 shares changed hands in those 10 minutes, 30.8 times the stock's normal volume for that stretch of the session. The headline crossed in pre-market trading, 2 hours 45 minutes before the 9:30 ET open.
Earlier MRNA headlines and the measured reaction
MoveSurge measured ten earlier Moderna headlines with an attributed reaction between Aug 8, 2026 and Nov 5, 2026. The largest was +64.73% in 15 minutes, on Aug 19, 2026.
- Nov 5, 2026, 17:24 ET: “Health Canada authorizes Moderna’s mRNA influenza and combined influenza-COVID-19 vaccines” (-3.12% in 10 minutes)
- Nov 4, 2026, 11:06 ET: “Moderna advances its investigational Bundibugyo ebolavirus vaccine toward a Phase 2/3 study” (+1.30% in 10 minutes)
- Oct 26, 2026, 15:52 ET: “Moderna (MRNA) CEO says the melanoma vaccine will be effective against additional cancers” (+0.77% in 10 minutes)
- Oct 23, 2026, 09:38 ET: “ESMO says it cannot establish whether the Moderna-Merck data leak stemmed from human error, a technical problem or another cause” (+6.41% in 10 minutes)
- Oct 22, 2026, 12:49 ET: “Early data leaks are cited as the reason for Moderna (MRNA) downside (link below) - UNCONFIRMED” (-0.88% in 10 minutes)
- Sep 14, 2026, 10:39 ET: “Moderna (MRNA) reaffirms plan to break even by 2028 with 2026 revenue growth of up to 10%” (+1.10% in 10 minutes)
Moderna at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $103.15 billion (as of Nov 6, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Moderna stock on November 6, 2026?
At 06:45:00 ET, this headline crossed: “Moderna says it is conducting a limited U.S. launch of its seasonal influenza vaccine for the 2026–2027 season, with approval coming after the annual contracting cycle”. The stock rose 6.97% in the next 10 minutes.
How far did MRNA move after the headline?
From $237.00 just before the headline to $253.51 10 minutes later, a +6.97% move.
What else has moved MRNA stock recently?
The two largest measured reactions before November 6, 2026: Oct 23, 2026, ESMO says it cannot establish whether the Moderna-Merck data leak stemmed from human error, a technical problem or another cause (+6.41% in 10 minutes); Nov 5, 2026, Health Canada authorizes Moderna’s mRNA influenza and combined influenza-COVID-19 vaccines (-3.12% in 10 minutes).
Sources
-
MRNA headline and measured reaction, Nov 6, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Go live — 7 days for $29 Watch live headlines -- free